Comparative pathology of breast cancer in a randomised trial of screening

T. J. Anderson, J. Lamb, P. Donnan, W. Hepburn, A. Smith, R. J. Prescott, F. E. Alexander, A. Huggins, B. B. Muir, A. E. Kirkpatrick, U. Chetty, P. Forrest

Research output: Contribution to journalArticlepeer-review

71 Citations (Scopus)

Abstract

In the Edinburgh Randomised Breast Screening Project (EBSP) to December 1988 there were 500 cancers in the study population invited to screening and 340 cancers identified in the control population. The size and negative lymph node status characteristics of invasive cancers from the two populations were significantly different (p<0. 05). The cancers detected by screening were predominantly ‘early stage’, with 16% noninvasive (PTIS) and 42% invasive stage I (pTl node negative), whereas cancers were frequently ‘late stage’ (more than pT2) and inoperable in nonattenders (44%) and controls (36%). Grouped according to customary size ranges of invasive cancers, the proportion of cases lymph node positive differed in those screen detected compared with controls, but the benefit in favour of screen detection was not constant. In comparisons of cancers detected at prevalence and incidence screens, as a test of conformity with screening theory, no significant differences were apparent according to size and lymph node status, yet the characteristics of histological type of cancer discriminated significantly (P < 0. 05). When these same histological characteristics were used to compare survival, the capacity to separate invasive cancers into two groups having good and poor survival probabilities was evident, with a significant improvement for the screen detected poor survival group compared with controls (P < 0. 05).

Original languageEnglish
Pages (from-to)108-113
Number of pages6
JournalBritish Journal of Cancer
Volume64
Issue number1
DOIs
Publication statusPublished - 1 Jan 1991

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Comparative pathology of breast cancer in a randomised trial of screening'. Together they form a unique fingerprint.

Cite this